Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Guidance Priorities For FY 2022 Include Transitioning EUAs; List Includes CDS Software Again

Executive Summary

The US agency’s device center on 26 October published its A and B lists of guidance documents it will prioritize in fiscal year 2022, including drafting guidances to transition emergency use authorized products to full marketing status, and finalizing a clinical decision support software guidance that’s been four years in the making.

You may also be interested in...



Digital Health Roundup: Digital Therapeutics Push Ahead On Standards, Coverage; FDA’s Software Guidance

In this roundup feature focusing on developments in digital health, we highlight the key news and announcements from October.

EUA Transition Process: 4 Things FDA Wants You To Know

A US FDA regulatory expert offers insight into what companies can expect from the agency as it braces to transition potentially hundreds of emergency use authorized (EUA) products to full marketing authorization.

US, UK, Canada Agree On Good Machine Learning Practices

The principals recommended by the three countries could be the foundation for how their regulatory bodies intend to regulate future AI/ML products.

Related Content

Topics

UsernamePublicRestriction

Register

MT144629

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel